Company Profile

Divi's Laboratories is currently trading at Rs. 3988.50, up by 147.75 points or 3.85% from its previous closing of Rs. 3840.75 on the BSE.

The scrip opened at Rs. 3855.00 and has touched a high and low of Rs. 4018.00 and Rs. 3840.75 respectively. So far 17087 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 4072.35 on 04-Jan-2024 and a 52 week low of Rs. 3050.15 on 22-May-2023.

Last one week high and low of the scrip stood at Rs. 4018.00 and Rs. 3674.20 respectively. The current market cap of the company is Rs. 104872.04 crore.

The promoters holding in the company stood at 51.92%, while Institutions and Non-Institutions held 36.89% and 11.19% respectively.

Divi's Laboratories is in the process of entering into a long-term supply agreement with a customer and is planning for capacity addition at its manufacturing facility with an estimated investment between Rs 650 crore to Rs 700 crore, to be funded from internal accruals. The proposed facility is expected to be operational around January 2027. Due to the confidentiality agreement signed with the customer, the Company is not permitted to disclose any further quantitative details.

Divi's Laboratories is one of the leading pharmaceutical companies in the world.

Divi's Laboratories is in the process of entering into a long-term supply agreement with a customer and is planning for capacity addition at its manufacturing facility with an estimated investment between Rs 650 crore to Rs 700 crore, to be funded from internal accruals. The proposed facility is expected to be operational around January 2027. Due to the confidentiality agreement signed with the customer, the Company is not permitted to disclose any further quantitative details.

Divi's Laboratories is one of the leading pharmaceutical companies in the world.

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Divi’s Laboratories has submitted the details as required under Para B of Part A of Schedule III of the Regulations read with Circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

The above information is a part of company’s filings submitted to BSE.

Divi's Laboratories has informed that it enclosed certificate dated April 10, 2024 obtained from V. Bhaskara Rao & Co., Practicing Company Secretaries for the year ended March 31, 2024, pursuant to Regulation 40(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Pursuant to the Company’s Code of Conduct for Prevention of Insider Trading (the Code), Divi’s Laboratories has informed that the Trading Window for dealing in securities of the Company will remain Closed for all Designated Persons and their Immediate Relatives, as well as Insiders covered under the Code, from April 01, 2024, till 48 hours after the declaration of audited financial results for the fourth quarter and year ending March 31, 2024. The date of Board meeting for declaration of the financial results of the Company for the fourth quarter and year ending March 31, 2024, will be intimated in due course.

The above information is a part of company’s filings submitted to BSE.